宫颈癌患者PIK3CA突变与拷贝数变异状态及放化疗后生存
本研究在单中心纳入1998至2014年确诊为FIGO IB-IVA期、接受根治性放化疗的宫颈癌患者,检测治疗前肿瘤标本的PI3K/AKT通路突变及PIK3CA拷贝数变异。PI3K/AKT通路突变常见,PIK3CA突变单因素与较差总生存相关,调整临床因素后关联未维持。
要点
- 在161例成功测序的肿瘤中,60例(37.3%)存在PI3K/AKT通路突变,50例(30.1%)存在PIK3CA热点突变。
- 154例成功分析拷贝数变异中,79例(59.2%)存在PIK3CA拷贝数增加。
- 单因素分析中PIK3CA突变与较差总生存相关(HR 1.73;95%CI 1.03-2.92;p=.037),但与无进展生存无关(HR 1.38;0.84-2.28;p=.204)。
核心结论
- PI3K/AKT通路突变在宫颈癌中常见。
- 考虑PIK3CA突变状态与拷贝数变异状态可能对预测宫颈癌患者结局重要。
研究设计与样本
- 研究为单中心队列,纳入1998至2014年确诊为FIGO IB-IVA期、接受根治性放化疗的宫颈癌患者,使用治疗前存档标本。
- 190例患者有可用治疗前肿瘤标本,其中161例肿瘤成功测序;154例成功分析PIK3CA拷贝数变异。
- 突变状态通过二代测序确定,PIK3CA拷贝数变异通过数字PCR评估。
主要发现
- 190例患者中位总生存为57.4个月,中位无进展生存为46.0个月。
- 161例成功测序肿瘤中60例(37.3%)有PI3K/AKT通路突变,50例(30.1%)有PIK3CA热点突变。
- 154例成功分析拷贝数变异中79例(59.2%)有PIK3CA拷贝数增加。
- 单因素分析:PIK3CA突变与较差总生存相关(HR 1.73;95%CI 1.03-2.92;p=.037),与无进展生存无关(HR 1.38;0.84-2.28;p=.204)。
- 单因素分析:无任何PI3K/AKT通路突变与较好总生存相关(HR 1.68;95%CI 1.01-2.81;p=.046),与无进展生存无关(HR 1.50;0.93-2.43;p=.202)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to describe the prognostic value of PI3K/AKT pathway mutations in a large cohort of patients with cervical cancer. EXPERIMENTAL DESIGN: Patients with pre-treatment archival specimens, diagnosed with FIGO stages IB-IVA cervical cancer between 1998 and 2014 and treated with radical, curative intent chemoradiotherapy (CRT) at a single center were identified. Mutational status was determined by next generation sequencing and PIK3CA copy number (CNV) was assessed by digital PCR. RESULTS: 190 patients with available pre-treatment tumor specimens were identified. Median OS and PFS were 57.4 and 46.0 months, respectively. A total of 161 tumors were successfully sequenced; 60 (37.3%) had PI3K/AKT pathway mutations, with 50 (30.1%) having PIK3CA hotspot mutations. PIK3CA CNV gain was noted in 79 (59.2%) of the 154 successfully analyzed. On univariate analysis, PIK3CA mutation was associated with poor OS (HR 1.73; 95% CI: 1.03-2.92; p = .037) but not PFS (HR 1.38; 0.84-2.28; p = .204). Absence of any PI3K/AKT pathway mutation was associated with improved OS (HR 1.68; 1.01-2.81; p = .046) but not PFS (HR 1.50; 0.93-2.43; p = .202). Associations were not maintained when adjusting for clinical factors. On univariate analysis, PIK3CA mutation positive, CNV normal tumors were associated with poorer OS (HR 2.55; 1.18-5.50; p = .017) and trend to worse PFS (HR 1.87; 0.90-3.83; p = .094) when compared to those with CNV gain and wildtype PIK3CA. CONCLUSIONS: PI3K/AKT pathway mutations are common in cervical cancer. Consideration of PIK3CA mutational status with CNV status may be important in predicting outcome in cervical cancer patients.
引用
- Martell K, McIntyre JB, Kornaga EN, et al. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer. Gynecol Oncol. 2020. PMID: 32653099. doi:10.1016/j.ygyno.2020.06.506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。